869185-85-3
869185-85-3 結(jié)構(gòu)式
基本信息
SB 203580, Hydrochloride - CAS 869185-85-3 - Calbiochem
RWJ 64809 HYDROCHLORIDE
SB203580 HYDROCHLORIDE
SB-203580 HYDROCHLORIDE
物理化學性質(zhì)
安全數(shù)據(jù)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-10256AR | SB 203580鹽酸鹽 Adezmapimod hydrochloride (Standard) | 869185-85-3 | 5 mg | 990元 |
| 2026/06/05 | HY-10256AR | SB 203580鹽酸鹽 Adezmapimod hydrochloride (Standard) | 869185-85-3 | 10 mg | 1485元 |
| 2026/06/05 | HY-10256AR | SB 203580鹽酸鹽 Adezmapimod hydrochloride (Standard) | 869185-85-3 | 25 mg | 2520元 |
常見問題列表
|
p38 50 nM (IC 50 ) |
p38β2 500 nM (IC 50 ) |
SB 203580 (preincubated with 0-30 μM for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2) prevents the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC
50
of 3-5 μM.
SB203580 blocks PKB phosphorylation (IC
50
3-5 μM). SB203580 inhibitsthe phosphorylation of Ser473 in a dose-dependent manner in both CT6 and activated human T cells and IL-2-responsive BA/F3 F7 B cells.
Cell Proliferation Assay
| Cell Line: | CT6, BA/F3 cell line F7, and PBMC/T cells |
| Concentration: | 0-30 μM |
| Incubation Time: | Preincubated with 0-30 μM SB203580 for 1 h and cultured for 24 h in the presence of 20 ng/mL IL-2 |
| Result: | Prevented the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC 50 of 3-5 μM. |
Western Blot Analysis
| Cell Line: | CT6 cells, activated human T cells, and BA/F3 F7 cells |
| Concentration: | 0-30 μM |
| Incubation Time: | Preincubated with 0-30 μM SB203580 for 1 h before stimulating with 20 ng/mL IL-2 for 5 min |
| Result: | Inhibited the phosphorylation of PKB at Ser473 in a dose-dependent manner. |
SB203580 (5 mg/kg/day; intra peritoneal injected daily for 16 consecutive days, in female atymic Nu/Nu mice) treatment, p38WT tumors show a significantly smaller tumor burden when compared with p38TM tumors that were treated in parallel.
| Animal Model: | Six-week-old female atymic Nu/Nu mice CAL27 p38WT and p38TM tumors |
| Dosage: | 5 mg/kg/day |
| Administration: | Intra peritoneal injected daily for 16 consecutive days |
| Result: | After 2 weeks treatment, CAL27 p38WT tumors were significantly smaller; CAL27 p38TM tumors were not affected by the p38 inhibitor (n=10). |